A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06874335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT06874335
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 19, 2025
- Primary completion
- Feb 28, 2029
- Completion
- Feb 28, 2029
- Last update posted
- Jul 8, 2026
2025 – 2029
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site-111 | Newport Beach | California | 92663 | Recruiting |
| Site-107 | Denver | Colorado | 80218 | Recruiting |
| Site-108 | Lake Mary | Florida | 32746 | Withdrawn |
| Site-121 | Miami | Florida | 33136 | Recruiting |
| Site-118 | Orlando | Florida | 32804 | Recruiting |
| Site-120 | Ann Arbor | Michigan | 48109 | Recruiting |
| Site-110 | Detroit | Michigan | 48201 | Recruiting |
| Site-115 | Durham | North Carolina | 27710 | Recruiting |
| Site-122 | Cleveland | Ohio | 44195 | Recruiting |
| Site-112 | Myrtle Beach | South Carolina | 29572 | Recruiting |
| Site-116 | Nashville | Tennessee | 37203 | Recruiting |
| Site-103 | Austin | Texas | 78758 | Recruiting |
| Site-104 | Houston | Texas | 77030 | Recruiting |
| Site-101 | Irving | Texas | 75039 | Recruiting |
| Site-105 | San Antonio | Texas | 78229 | Recruiting |
| Site-106 | West Valley City | Utah | 84119 | Recruiting |
| Site-102 | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06874335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2026 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06874335 live on ClinicalTrials.gov.